CLOVES Syndrome Awareness Day 2026: Building a Rare-Care Control Tower
- Posted by Greg Wahlstrom, MBA, HCM
- Posted in 2026 Healthcare Observances Calendar, Health Observance Calendar
Rare-Care Control Tower
CLOVES Syndrome Awareness Day 2026: Building a Rare-Care Control Tower
Turn a one-day awareness signal into a coordinated operating model for complex vascular anomalies, genomic care, procedural safety, treatment oversight, and lifelong partnership.
The leadership signal: rarity does not excuse fragmentation
CLOVES Syndrome Community observes CLOVES Awareness Day every August 3. In 2026, the date falls on a Monday, giving healthcare organizations a clear opening to connect public education with an operational review of how patients with complex, lifelong conditions move through the system.
CLOVES stands for congenital lipomatous overgrowth, vascular malformations, epidermal nevi, and scoliosis or skeletal and spinal anomalies. The organization’s clinical overview explains that presentation varies widely and that most people have a combination of findings rather than every feature in the acronym. CLOVES is part of PIK3CA-related overgrowth spectrum, or PROS, and is associated with somatic PIK3CA variants. Because the change arises after conception and may be present in only some tissues, the diagnostic journey can require specialized examination, imaging, and testing of affected tissue.
Build one pathway around a highly variable condition
The NIH-hosted GeneReviews chapter on PROS describes a spectrum that can affect adipose tissue, vessels, bone, skin, the brain, and other organs. Boston Children’s Hospital likewise identifies CLOVES as a rare vascular anomaly that can involve soft tissues, blood and lymphatic vessels, bones, and skin. These are not separate service-line problems. They are connected clinical and operational risks that require a coordinated plan tailored to the individual.
Recognize
Equip primary, pediatric, prenatal, emergency, and specialty teams to identify concerning patterns and refer without overpromising a diagnosis.
Confirm
Coordinate expert review, imaging, genetics, consent, tissue strategy, and plain-language communication of results.
Plan
Bring vascular anomalies, surgery, interventional radiology, orthopedics, hematology, rehabilitation, and other needed disciplines to one plan.
Protect
Standardize individualized procedural, medication, bleeding, clotting, infection, pain, and mobility safeguards.
Sustain
Support school, work, behavioral health, financial access, transition to adult care, and research opportunities across the lifespan.
A center does not need every specialty on site to be accountable. It does need defined referral relationships, image-sharing capability, a rapid escalation route, and a named clinician who can reconcile recommendations. This is where the broader lessons from The Healthcare Executive’s Rare Disease Day leadership brief become concrete: inclusion in strategy, data, and care navigation is a system responsibility.
Six decisions executives should make before the campaign
1. Name the clinical home and navigator
Define which program owns intake, record collection, multidisciplinary review, family communication, and follow-up. Publish criteria for internal consultation and referral to a vascular anomalies center. Track rejected and delayed referrals so capacity gaps become visible to leadership.
2. Create a shared, portable care plan
Build a concise summary of diagnoses, manifestations, prior procedures, imaging, medications, specialists, emergency considerations, and patient priorities. Make it available across emergency, inpatient, perioperative, and outpatient settings, and give patients an accessible version they can carry outside the system.
3. Require a pre-procedure risk huddle
Complex vascular and lymphatic malformations can change bleeding, thrombosis, wound, positioning, and recovery considerations. Require case-specific planning among the proceduralist, anesthesia, hematology, radiology, pharmacy, rehabilitation, and the patient or caregiver. Avoid a generic CLOVES protocol that ignores individual anatomy and history.
4. Govern systemic therapy as a program
The current FDA prescribing information for alpelisib includes patients age two years and older with severe PROS manifestations who require systemic therapy. The label also carries important warnings and monitoring requirements. Specialist selection, informed decision-making, baseline assessment, laboratory surveillance, interaction review, symptom escalation, adherence, response documentation, and financial access should operate as one governed pathway, not as isolated pharmacy tasks.
5. Design for equity and daily life
Rare-disease expertise may require long travel, time away from work or school, repeated imaging, mobility support, interpretation, and complex authorization. Monitor access by payer, geography, language, disability, age, and referral source. Connect families with lodging, transportation, financial counseling, rehabilitation, and psychosocial support early.
6. Put lived experience into governance
Compensate patients and caregivers who advise on scheduling, education, portal design, procedure preparation, research communication, and transition planning. The Healthcare Executive’s guide to C-suite patient advocacy offers a useful foundation. Partnership should influence decisions, not merely validate materials after they are finished.
Use a handoff ledger that reveals delay and risk
Small cohorts still deserve disciplined measurement. Report counts with context, protect privacy, and avoid public slices that could identify a person. The board needs trends in access, reliability, safety, experience, and learning, while the clinical team needs patient-level work queues that support action.
| Signal | Measure | Owner | Escalation trigger |
|---|---|---|---|
| Access | Days from referral to expert review; referrals closed without a destination | Program leader | Delay above standard or repeated payer and geography pattern |
| Coordination | Patients with current shared care plan and named clinical home | Navigator | Missing owner, outdated plan, or unresolved conflicting recommendation |
| Procedural safety | Cases with documented multidisciplinary risk huddle and follow-up | Perioperative leader | Urgent case without review or unplanned safety event |
| Therapy | Eligible patients completing monitoring and response assessment on time | Prescriber and pharmacy | Missed laboratory check, concerning symptom, access interruption, or undocumented response |
| Experience | Caregiver burden, travel, communication, goal attainment, and transition readiness | Experience officer | Reported confusion, avoidable travel, unmet support need, or transition gap |
| Learning | Registry and study opportunities discussed with eligible patients | Research lead | No documented discussion or inequitable enrollment pattern |
Measure time between handoffs, not only completed visits and procedures.
Track travel, denials, missed work or school, and communication breakdowns.
Document whether goals, tradeoffs, and lived experience changed the plan.
An August 3 activation plan that lasts beyond one day
Before August 3
- Audit the last 12 months of referrals, handoffs, procedures, denials, and transition gaps.
- Confirm referral partners and emergency escalation contacts.
- Review public materials with patients, caregivers, and clinical experts.
On Awareness Day
- Share accurate information from CLOVES Syndrome Community and explain PROS in plain language.
- Host a multidisciplinary case-learning session using a de-identified journey map.
- Publish one accountable improvement commitment with an owner and due date.
During the next 60 days
- Launch or repair the shared care plan and navigator work queue.
- Test one pre-procedure huddle and one external referral handoff.
- Report baseline measures to quality leadership and invite patient review.
The CLOVES Syndrome Registry, launched by CLOVES Syndrome Community and the National Organization for Rare Disorders, is a patient-reported natural history study open internationally. Leaders should create an ethical, consistent process for sharing registry and clinical-study opportunities without pressure, with appropriate consent, privacy, and conflict-of-interest safeguards. Research access is part of learning-system maturity.
Make the system easier to navigate than the diagnosis
CLOVES Syndrome Awareness Day 2026 is a test of whether an organization can coordinate complexity without transferring the burden to patients and families. A credible response includes an accountable clinical home, expert referral relationships, a portable care plan, individualized procedural safeguards, disciplined therapy governance, equitable support, and a dashboard that exposes unfinished handoffs.
Awareness earns trust only when it changes operations. On August 3, choose one fragmented handoff and close it. Then keep measuring until reliable, patient-centered coordination becomes the normal way the system works.
Sources and related executive reading
Authoritative sources
- CLOVES Syndrome Community: Awareness Day
- CLOVES Syndrome Community: What Is CLOVES?
- GeneReviews: PIK3CA-Related Overgrowth Spectrum
- Boston Children’s Hospital: CLOVES Syndrome
- FDA: Current VIJOICE Prescribing Information
- CLOVES Syndrome Community and NORD: Natural History Study
- Peer-reviewed work-up and treatment strategies for PROS
Related reading from The Healthcare Executive
Clinical note: This executive brief is educational and does not provide individual diagnosis or treatment recommendations. Clinical decisions, surveillance, procedures, and medications must be individualized by qualified clinicians using current guidance and the patient’s circumstances. Source content was reviewed August 3, 2026.